LXR 1035

Drug Profile

LXR 1035

Latest Information Update: 03 May 2000

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LXR Biotechnology
  • Class Antineoplastics; Lysophospholipids
  • Mechanism of Action Apoptosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Myocardial infarction; Stroke

Most Recent Events

  • 03 May 2000 Discontinued-Preclinical for Myocardial infarction in USA (Unknown route)
  • 03 May 2000 Discontinued-Preclinical for Stroke in USA (Unknown route)
  • 03 Dec 1998 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top